PURPOSE: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT(3)) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids.METHODS: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting and no rescue therapy during overall phase (0-120 h) was the primary endpoint. Complete control (CC) defined as CR and only mild nausea was a secondary endpoint.RESULTS: Eighty-six evaluable patients entered in the study. A CR was observed in 74 patients (86.0%) during the overall phase; the CR during the acute (0-24 h) and delayed (24-120 h) phases was 90.7% and 88.4%, respectively. CC was 89.5% during the acute and 84.9% during the delayed phase; the overall CC was 82.6%.CONCLUSIONS: This was the first trial, which demonstrated the efficacy of a single dose of palonosetron in control CINV in patients with aggressive non-Hodgkin's lymphoma receiving MEC regimen containing steroids.
Single-dose Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containig steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL) / Di Renzo, N.; Montanini, Antonella; Mannina, D.; Dondi, Alessandra; Muci, S.; Mancuso, S.; De Polis, M. R.; Plati, C.; Stelitano, C.; Patti, C.; Olivieri, A.; Liardo, E.; Buda, G.; Cantaffa, R.; Federico, Massimo. - In: SUPPORTIVE CARE IN CANCER. - ISSN 0941-4355. - STAMPA. - 19(2011), pp. 1505-1510. [10.1007/s00520-010-0974-y]
Data di pubblicazione: | 2011 | |
Titolo: | Single-dose Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containig steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). | |
Autore/i: | Di Renzo, N.; Montanini, Antonella; Mannina, D.; Dondi, Alessandra; Muci, S.; Mancuso, S.; De Polis, M. R.; Plati, C.; Stelitano, C.; Patti, C.; Olivieri, A.; Liardo, E.; Buda, G.; Cantaffa, R.; Federico, Massimo | |
Autore/i UNIMORE: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.1007/s00520-010-0974-y | |
Rivista: | ||
Volume: | 19 | |
Pagina iniziale: | 1505 | |
Pagina finale: | 1510 | |
Codice identificativo ISI: | WOS:000294559000005 | |
Codice identificativo Scopus: | 2-s2.0-80052489830 | |
Codice identificativo Pubmed: | 20694798 | |
Citazione: | Single-dose Palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containig steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL) / Di Renzo, N.; Montanini, Antonella; Mannina, D.; Dondi, Alessandra; Muci, S.; Mancuso, S.; De Polis, M. R.; Plati, C.; Stelitano, C.; Patti, C.; Olivieri, A.; Liardo, E.; Buda, G.; Cantaffa, R.; Federico, Massimo. - In: SUPPORTIVE CARE IN CANCER. - ISSN 0941-4355. - STAMPA. - 19(2011), pp. 1505-1510. [10.1007/s00520-010-0974-y] | |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
art%3A10.1007%2Fs00520-010-0974-y.pdf | Versione dell'editore (versione pubblicata) | Open Access Visualizza/Apri |
Pubblicazioni consigliate

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris